250 related articles for article (PubMed ID: 25669446)
21. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K
In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230
[TBL] [Abstract][Full Text] [Related]
22. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of miR-10b expression in circulating tumor cells.
Gasch C; Plummer PN; Jovanovic L; McInnes LM; Wescott D; Saunders CM; Schneeweiss A; Wallwiener M; Nelson C; Spring KJ; Riethdorf S; Thompson EW; Pantel K; Mellick AS
Sci Rep; 2015 Nov; 5():15980. PubMed ID: 26522916
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.
Aaltonen KE; Novosadová V; Bendahl PO; Graffman C; Larsson AM; Rydén L
Oncotarget; 2017 Jul; 8(28):45544-45565. PubMed ID: 28489591
[TBL] [Abstract][Full Text] [Related]
25. Expression profiling of circulating tumor cells in metastatic breast cancer.
Lang JE; Scott JH; Wolf DM; Novak P; Punj V; Magbanua MJ; Zhu W; Mineyev N; Haqq CM; Crothers JR; Esserman LJ; Tripathy D; van 't Veer L; Park JW
Breast Cancer Res Treat; 2015 Jan; 149(1):121-31. PubMed ID: 25432738
[TBL] [Abstract][Full Text] [Related]
26. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
[TBL] [Abstract][Full Text] [Related]
27. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
Fehm T; Becker S; Duerr-Stoerzer S; Sotlar K; Mueller V; Wallwiener D; Lane N; Solomayer E; Uhr J
Breast Cancer Res; 2007; 9(5):R74. PubMed ID: 17963511
[TBL] [Abstract][Full Text] [Related]
28. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
[TBL] [Abstract][Full Text] [Related]
29. Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells.
Sheng Y; Wang T; Li H; Zhang Z; Chen J; He C; Li Y; Lv Y; Zhang J; Xu C; Wang Z; Huang C; Wang L
Oncotarget; 2017 Jan; 8(5):8801-8806. PubMed ID: 28187533
[TBL] [Abstract][Full Text] [Related]
30. A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM
Lampignano R; Yang L; Neumann MHD; Franken A; Fehm T; Niederacher D; Neubauer H
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858218
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cells in breast cancer--current status and perspectives.
Banys-Paluchowski M; Krawczyk N; Meier-Stiegen F; Fehm T
Crit Rev Oncol Hematol; 2016 Jan; 97():22-9. PubMed ID: 26563820
[TBL] [Abstract][Full Text] [Related]
32. Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
Bystricky B; Cierna Z; Sieberova G; Janega P; Karaba M; Minarik G; Benca J; Sedlackova T; Jurisova S; Gronesova P; Pindak D; Macuch J; Mardiak J; Mego M
Anticancer Res; 2017 May; 37(5):2727-2734. PubMed ID: 28476852
[TBL] [Abstract][Full Text] [Related]
33. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
[TBL] [Abstract][Full Text] [Related]
34. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
35. A microchip filter device incorporating slit arrays and 3-D flow for detection of circulating tumor cells using CAV1-EpCAM conjugated microbeads.
Kim YJ; Koo GB; Lee JY; Moon HS; Kim DG; Lee DG; Lee JY; Oh JH; Park JM; Kim MS; Woo HG; Kim SI; Kang P; Choi W; Sim TS; Park WY; Lee JG; Kim YS
Biomaterials; 2014 Aug; 35(26):7501-10. PubMed ID: 24917030
[TBL] [Abstract][Full Text] [Related]
36. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
[TBL] [Abstract][Full Text] [Related]
37. [Detection and clinical significance of circulating tumor cells in peripheral blood of breast cancer patients].
Cai QQ; Huang HQ; Lin TX; Jiang WQ
Ai Zheng; 2005 Jul; 24(7):837-41. PubMed ID: 16004811
[TBL] [Abstract][Full Text] [Related]
38. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
39. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.
Nunes RA; Li X; Kang SP; Burstein H; Roberts L; Carney W; Blackwell K; Ryan P; Borges V; Iglehart JD; Friedman P; Harris LN
Int J Biol Markers; 2009; 24(1):1-10. PubMed ID: 19404916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
